Informational Presentation: WHO Biological Standards Summary of January 29-30, 2007 WHO Meeting with WHO Collaborating Centres for Biological Standards.

Slides:

Advertisements

Similar presentations

Summary of 3 rd CEWG meeting by Chair and Vice-Chair Open Session CEWG on R&D Financing and Coordination November 18, 2011.

Advertisements

WHO Norms and Standards:

World Bank Financial Management Sector September 2010.

State Health Departments: Focused on the Next Level Ann Robbins Texas Department of State Health Services National Alliance of State and Territorial AIDS.

Thailand National Focal Point for IFCS Chemical Safety Section Food and Drug Administration Ministry of Public Health July 2003.

Merton V. Smith, Ph.D., J.D. Director International Programs Center for Veterinary Medicine U.S. Food and Drug Administration Governance of Veterinary.

3rd WHO Prequalification Stakeholders Meeting

Yi-Chen Yang, Drug Biology Division Bureau of Food and Drug Analysis Department of Health, Taiwan Collaborative study for establishment of the first national.

Linearity Panels HIV RNA, HCV RNA, HBV DNA, and CMV DNA

CBER's policies on assay regulation: Definitions of assay performance characteristics Andrew I. Dayton, M.D., Ph.D. CBER.

Evaluation Cooperation Group Presentation to the DAC Network on Development Evaluation 9/10 November 2004 Role and functioning of the Evaluation Cooperation.

PROFICIENCY TESTING OF IN-HOUSE NAT ASSAYS USED FOR BLOOD SCREENING XXI SoGAT International Working Group Meeting on the Standardization of NAT for the.

PEER REVIEW PILOT EXERCISE Paris, December BWC – MSP December 2014.

1 Theme-based Research Scheme Briefing Session 12 April 2010.

ICBS Master Panels for Kit Evaluation: HCV, HBV, and HIV ( Howard A. Fields, Ph.D. Susan Diaz, MPH Division of Viral Hepatitis Centers.

Prof. Musabaev E.I. Quality Control Systems for Hepatitis B and C diagnostics in Uzbekistan.

Reentry for Donors Deferred Based on Anti-HBc Test Results November 3, 2005 BPAC Meeting FDA/CBER/OBRR/DETTD.

PHS GUIDELINE FOR REDUCING TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS, HEPATITIS B VIRUS AND HEPATITIS C VIRUS THROUGH SOLID ORGAN TRANSPLANTATION ACOT.

1 Capacity Building: Strategy and Action Plan GEF-UNDP Strategic Partnership Capacity Development Initiative.

Update on the Replacement of the HCV RNA International Standard Sally Baylis & Alan Heath, NIBSC SoGAT XX, Warsaw June 2007.

WHO Norms and Standards: Blood Products & related Biologicals Dr Ana Padilla, Blood Products & related Biologicals Medicines Policy and Standards Department.

SOGAT Validation of HCV-RNA detection in small test pools on cadaveric samples Marco Koppelman #, Theo Cuypers #, Mirjam de Waal #, Maarten.

Michael Chudy, Paul-Ehrlich-Institut SoGAT XVIII, Bethesda MD

ACADs (08-006) Covered Keywords Commission, regulation, advisory, standards. Description This presentation provides general information about each of the.

CE MARKING OF IVDDs - the NIBSC perspective Morag Ferguson Division of Virology.

Enhancing International Capacity to Meet SPS Standards Mo Salman Animal Population Health Institute College of Veterinary Medicine and Biomedical Sciences.

M. Chudy | 12 June |1 | SoGAT XX, Warsaw, Poland June 2007 Michael Chudy, WHO; Geneva, Switzerland Development of Biological Reference Preparations.

The approach taken by a Central/Eastern European Blood Transfusion Organisation: POLAND Magdalena Łętowska National Centre for Transfusion Medicine Warsaw,

Establishment of the 1st WHO International Standard for Detection of Antibodies to Hepatitis B Virus Core Antigen (anti-HBc) SoGAT XXI 29 May 2009 Dr.

Standardisation of P. falciparum HBV, HCV and NAT Sally Baylis, NIBSC SoGAT XVIII.

RHSC Meeting Kampala, May 2010 Quality for Medicines The Global Fund approach Sophie Logez Manager, QA and Data Quality Pharmaceutical Management.

Yi-Chen Yang, Yu-Hsuan Chen, Show-Lan Chiu, Hwei-Fang Cheng Drug Biology Division, Bureau of Food and Drug Analysis Department of Health, Taiwan, ROC National.

SoGAT XVII/Paris, 2004 Proficiency Testing of In-House Developed HIV-1 NAT for Blood Screening Michael Chudy, Paul-Ehrlich-Institut Division of Virology,

Third OIE Global Conference on Animal Welfare Kuala Lumpur, Malaysia The OIE PVS Pathway Dr. Mariela Varas OIE International Trade Department.

Institutional Accreditation: What is it? Higher Learning Commission accredits degree- granting institutions in the North Central region. Assurance to the.

Yasser El-Wazir, MBBCh, PhD Director of quality Center, SCU Professor of Physiology Faculty of Medicine, Suez Canal University.

1 Preparation of Standard Paneled Plasma for HBV, HCV, and HIV-1 in Japan Hisao Yugi Japanese Red Cross Central Blood Center Study Group of the Ministry.

SoGAT June 14, 2006 HCV-RNA and HIV-RNA detection in small test pools of cadaveric samples for viral safety of tissue transplants Maarten Koot#,

CBER 1 Disease Associated Antibody Donor Program Rosia E. Nesbitt, BS, SBB(ASCP), CQA(ASQ) Consumer Safety Officer CBER, OBRR, DBA September 16, 2009.

Blood Products & related Biologicals: SoGAT, 28 May 09 1 |1 | Dr Ana Padilla, Blood Products & related Biologicals Essential Medicines and Pharmaceutical.

Update on the P. falciparum Standard & Replacement of the HBV & HCV International Standards Sally Baylis, NIBSC SoGAT XIX.

Student Education Service: Cross-Institutional Functional Management Teams October 2013 Kath Hodgson Student Education Service Programme Student Education.

Steering Committee Virtual Meeting February 27, 2012 Washington, DC NETWORK COMPONENT Ismael FOFANA AGRODEP Network Coordinator.

Preparation of HBV DNA reference standards and the experience of HBV NAT in Taiwan Dr. Hwei-Fang Cheng Department of Health, Taiwan.

The Male’ Declaration Proposal for Phase 4 Implementation.

Department of Labour Presentation of ILO 93 rd Conference to the Portfolio Committee on Labour 8 November 2005.

CBER Source Plasma Labeling Judy Ellen Ciaraldi BS, MT(ASCP)SBB, CQA(ASQ) CBER, OBRR, DBA September 16, 2009.

An Overall View of Standardization May 26, 2004 Indira Hewlett, Ph.D. CBER/FDA.

Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.

CE mark issues -- PEI view

CLIA Waiver for the OraQuick ® Rapid HIV-1 Antibody Test Elliot P. Cowan, Ph.D. Senior Regulatory Scientist Office of Blood Research and Review Center.

Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.

Epidemiology of Transfusion Transmitted Disease Sharyn Orton, MT(ASCP)SBB, M.S.P.H, Ph.D. candidate Project Leader, Transmissible Diseases Department American.

Team Leader, Technology Policy and Strategy, UNFCCC Mr Andrew Higham THE CANCUN AGREEMENTS, THE TECHNOLOGY MECHANISM AND TECHNOLOGY NEEDS ASSESSMENTS UNFCCC.

CBER Overview of Laboratory of Molecular Virology Indira Hewlett, Ph.D Laboratory Chief.

WHO Regional Workshop on Good Manufacturing Practices for Blood Establishments Dr Ana Padilla, Blood Products & related Biologicals Essential Medicines.

IX Annual General Meeting of PANCAP: St. George’s, Grenada October, 2009 To provide creative and dynamic services to PANCAP to enhance the regional.

CBER Update on status of West Nile virus test, lot release and validation panel development Indira Hewlett, Ph.D CBER/FDA Blood Products Advisory Committee.

Russian Information-Analytical APEC Center for Agricultural Biotechnology.

Saeko Mizusawa, Yoshiaki Okada

Progress of 2016 Work Plan implementation by HIV, TB&AI EG

Health and HIV Economics

Unit for Medical Systems and Devices at Ministry of Health

Medicines Control Council (MCC) &

Harvey Holmes, Clare Morris and Neil Berry Division of Retrovirology

Overview of vaccines prequalification

World Health Organization

Quality Assurance and Safety of Blood Products & Related Biologicals

Medicines Control Council (MCC) &

Supporting Implementation of the EDL

Presentation transcript:

Informational Presentation: WHO Biological Standards Summary of January 29-30, 2007 WHO Meeting with WHO Collaborating Centres for Biological Standards and Standardization Paul A. Mied, Ph.D. Blood Products Advisory Committee, 90 th Meeting August 16, 2007

CBER WHO Collaborating Centres for Biological Standards and Standardization l National Institute for Biological Standards and Control (NIBSC) l Paul-Ehrlich-Institut (PEI) l Center for Biologics Evaluation and Research (CBER)

CBER Meeting Convened by: The Quality Assurance and Safety: Blood Products and Related Biologicals (QSD) team, Department of Medicines Policy and Standards (PSM), World Health Organization (WHO)

CBER Objective of the Meeting To strengthen the development of WHO International Biological Reference Preparations for the control of in vitro diagnostic tests related to blood safety.

CBER Intended Use of the WHO Biological Reference Preparations Validation, quality control, assessment of comparability, and regulation on a global basis of blood safety-related in vitro diagnostic tests, contributing to a harmonized regulation of blood and blood products.

CBER Priority Projects Identified A. Replacement of Existing WHO Biological Reference Preparations Near Exhaustion: 1. Anti-HBs immunoglobulin (proposed 2 nd International Reference Preparation) 2. HCV RNA (proposed 3 rd International Standard) 3. Parvovirus B19 DNA (proposed 2 nd International Standard) 4. Anti-Syphilitic Standard (proposed 2 nd International Standard)

CBER Priority Projects Identified (Cont.) B. New WHO Biological Reference Preparations Needed: 5. HIV-1 Genotype Panel (proposed 2 nd International Reference Panel) 6. HIV-2 RNA International Standard 7. Anti-HIV Panel (proposed 2 nd International Reference Panel) 8. HBsAg and HBV DNA Genotype Panels

CBER Priority Projects Identified (Cont.) B. New WHO Biological Reference Preparations Needed: 9. Anti-HBc International Standard 10. Anti-HCV Panel 11. Anti-HTLV-I/II Panel 12. Anti-Plasmodium species Panel 13. Anti-Trypanosoma cruzi Preparation / Panel

CBER Priority Projects Identified (Cont.) C. Proposed WHO Biological Reference Preparations for Further Discussion: 14. HIV-2 RNA Genotype Panel 15. HCV Genotype Panel 16. Parvovirus B19 Genotype Panel 17. Anti-CMV Standard 18. WNV RNA Preparation / Pan Panel for arthropod-borne flaviviruses RNA

CBER Priority Projects Identified (Cont.) C. Proposed WHO Biological Reference Preparations for Further Discussion: 19. HCV Core Antigen Preparation 20. Anti-HHV-8 and HHV-8 DNA Preparations 21. TSE Blood Preparations 22. Blood-borne Bacteria Panel 23. Anti-Leishmania Panel

CBER Additional Agreements Among WHO Collaborating Centres l Need for exchange of epidemiological information l Established and new Biological Reference Preparations will be suitable for new technologies l Need for improved collaboration: meetings and telecons l Need to establish a network of all WHO Regions

CBER Plan of Action The Priority Projects to establish WHO Biological Reference Preparations to support international regulations for blood and blood products safety will form a five- year In Vitro Diagnostic strategic plan. This plan will be submitted to the ECBS for endorsement in October, 2007.